Fatty Liver
Conditions
Keywords
CT
Brief summary
This study investigates relationship between fatty liver prognosis and body composition analysis result based on non-contrast low dose CT in patients with fatty liver disease.
Interventions
DIAGNOSTIC_TESTNon-contrast low-dose abdomen CT
target effective dose: \< 1.5 mSv It is performed twice in 6-month interval.
DIAGNOSTIC_TESTFibroscan
Fibroscan is performed within a week of low-dose CT. It is used as a reference standard of hepatic fibrosis and steatosis.
DIAGNOSTIC_TESTbioelectrical impedance analysis (BIA)
BIA test is performed on the same day of low-dose CT. Commercially available model (Inbody 270) is used.
Sponsors
Seoul National University Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* metabolic dysfunction-associated fatty liver disease (fatty liver with overweight/obesity, or type II DM or other metabolic dysfunction) * or non-alcoholic fatty liver disease with liver function test abnormality * signed informed consent
Exclusion criteria
* chronic hepatitis B or C * other disease related to fatty liver such as glycogen storage disease, lipodystrophy, familial combined hyperlipidemia, hypobetalipoproteinemia, Weber-Christian syndrome or abetalipoproteinemia * on medication related to hepatic steatosis (tamoxifen, steroid, valproic acid, methotrexate, amiodarone) * diabetes after pancreatectomy * history of total parenteral nutrition in 6 months * pregnancy or nursing mother
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| relationship between body composition analysis result from CT and liver fat fraction | 6 month after CT acquisition | relationship between visceral fat volume fraction (obtained from CT analysis using automatic body segmentation, unitless (visceral fat fraction = visceral fat volume/total body volume)) and CAP value of fibroscan |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| ratio of appropriate non-contrast low dose abdomen CT acquisition & analysis | 6 month after CT acquisition | Number of CT scan with effective dose \< 1.5 mSv AND successful automatic body composition analysis (without manual editing) divided by total number of CT scan |
| relationship between body composition analysis result from CT and hepatic fibrosis | 6 month after CT acquisition | relationship between visceral fat volume fraction (CT analysis using automatic body segmentation, unitless (visceral fat fraction = visceral fat volume/total body volume)) and liver stiffness value of fibroscan |
| agreement between body composition analysis result from CT and bioelectrical impedance analysis (Inbody test) | 6 month after CT acquisition | agreement of visceral fat, subcutaneous fat, muscle amount between CT based body composition and Inbody test results |
Other
| Measure | Time frame | Description |
|---|---|---|
| incidence of incidental finding | 6 month after CT acquisition | incidentally detected findings on low-dose abdomen CT |
Countries
South Korea
Outcome results
None listed